SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Kintara Therapeutics, Inc. (KTRA) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KTRA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.21
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-404.86 |
$0.00 |
$-8.86M |
- |
| 2017 |
$-335.43 |
$0.00 |
$-8.08M |
- |
| 2018 |
$-266.96 |
$0.00 |
$-11.14M |
- |
| 2019 |
$-143.87 |
$0.00 |
$-7.41M |
- |
| 2020 |
$-48.39 |
$0.00 |
$-10.11M |
- |
| 2021 |
$-74.02 |
$0.00 |
$-38.32M |
- |
| 2022 |
$-25.80 |
$0.00 |
$-22.66M |
- |
| 2023 |
$-9.27 |
$0.00 |
$-14.65M |
- |
| 2024 |
$-3.23 |
$0.00 |
$-8.5M |
- |
| 2025 |
$-1.21 |
$0.00 |
$-22.65B |
- |
